Enhancing the permeation of marker compounds and enaminone anticonvulsants across Caco-2 monolayers by modulating tight junctions using zonula occludens toxin

被引:51
作者
Cox, DS
Gao, HL
Raje, S
Scott, KR
Eddington, ND
机构
[1] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Pharmacokinet Biopharmaceut Lab, Baltimore, MD 21201 USA
[2] Howard Univ, Coll Pharm Nursing & Allied Hlth Sci, Dept Pharmaceut Sci, Washington, DC 20059 USA
关键词
tight junctions; enaminones; zonula occludens toxin; paracellular transport; bioavailability;
D O I
10.1016/S0939-6411(01)00172-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Zonula occludens toxin (Zot), a protein elaborated from Vibrio cholerae, has been shown to be capable of reversibly opening tight junctions between intestinal cells The objective of this study was to examine the effect of Zot on the flux of various molecules across Caco-2 cell monolayers. In addition, the transport of a series of anticonvulsants, the enaminones was also evaluated in the presence of Zot. The flux of [C-14] mannitol, [C-14] inulin and various enaminones across Caco-2 cell monolayers (n = 6) was examined after pre-incubation for 1 h with Zot (0 or 4000 ng/ml) or phosphate-buffered saline (PBS). At the end of the incubation period, the flux of radiolabeled compounds or enaminones (1 X 10(-4) M) was assessed over a 2-h period. In addition, dose-response studies with Zot (0, 1000, 2000 or 4000 ng/ml) were performed using mannitol. The flux of both mannitol and inulin significantly increased (P < 0.05) in the presence of Zot. The transport of the enaminones with Zot ranged from 9.42 to 26.83 x 10(-5) cm/s vs. 4.68 to 13.83 x 10(-5) cm/s without Zot. Zot significantly increased the transport of all agents tested. This suggests that the co-administration of drugs with Zot may be a useful delivery strategy to increase the intestinal permeability and hence oral absorption of poorly bioavailable agents. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:145 / 150
页数:6
相关论文
共 21 条
[1]   CORRELATION BETWEEN ORAL-DRUG ABSORPTION IN HUMANS AND APPARENT DRUG PERMEABILITY COEFFICIENTS IN HUMAN INTESTINAL EPITHELIAL (CACO-2) CELLS [J].
ARTURSSON, P ;
KARLSSON, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 175 (03) :880-885
[2]   EFFECT OF CHITOSAN ON THE PERMEABILITY OF MONOLAYERS OF INTESTINAL EPITHELIAL-CELLS (CACO-2) [J].
ARTURSSON, P ;
LINDMARK, T ;
DAVIS, SS ;
ILLUM, L .
PHARMACEUTICAL RESEARCH, 1994, 11 (09) :1358-1361
[3]   EPITHELIAL TRANSPORT OF DRUGS IN CELL-CULTURE .1. A MODEL FOR STUDYING THE PASSIVE DIFFUSION OF DRUGS OVER INTESTINAL ABSORPTIVE (CACO-2) CELLS [J].
ARTURSSON, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1990, 79 (06) :476-482
[4]   Chitosan as a nasal delivery system: Evaluation of insulin absorption enhancement and effect on nasal membrane integrity using rat models [J].
Aspden, TJ ;
Illum, L ;
Skaugrud, O .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1996, 4 (01) :23-31
[5]  
BORCHARDT RT, 1996, MODELS ASSESSING DRU, P13
[6]   Determination of the enaminone DM5, an anti-epileptic agent, in mouse plasma and brain tissue by high-performance liquid chromatography with ultraviolet detection [J].
Cox, DS ;
Du, JP ;
Scott, KR ;
Gao, HL ;
Eddington, ND .
JOURNAL OF CHROMATOGRAPHY B, 2000, 749 (02) :191-196
[7]   SYNTHESIS AND ANTICONVULSANT ACTIVITY OF ENAMINONES [J].
EDAFIOGHO, IO ;
HINKO, CN ;
CHANG, HJ ;
MOORE, JA ;
MULZAC, D ;
NICHOLSON, JM ;
SCOTT, KR .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (15) :2798-2805
[8]   Enaminones-versatile therapeutic pharmacophores. Further advances [J].
Eddington, ND ;
Cox, DS ;
Roberts, RR ;
Stables, JP ;
Powell, CB ;
Scott, KR .
CURRENT MEDICINAL CHEMISTRY, 2000, 7 (04) :417-436
[9]   The enterotoxic effect of zonula occludens toxin on rabbit small intestine involves the paracellular pathway [J].
Fasano, A ;
Uzzau, S ;
Fiore, C ;
Margaretten, K .
GASTROENTEROLOGY, 1997, 112 (03) :839-846
[10]   Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model [J].
Fasano, A ;
Uzzau, S .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (06) :1158-1164